Swedish Orphan Biovitrum AB Sweden New York

TRYNGOLZA® recommended for EU approval by CHMP for familial chylomicronemia syndrome

Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission decision expected by Q4 2025View original content:https://www.prnewswire.co.uk/news-releases/tryngolza-olezarsen-recommended-for-eu-approval-by-chmp-for-familial-chylomicronemia-syndrome-fcs-302513906.html